These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 23057946)

  • 1. 'Watch and wait' as initial management for patients with follicular lymphomas: still a viable strategy?
    Hagemeister FB
    BioDrugs; 2012 Dec; 26(6):363-76. PubMed ID: 23057946
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Has the time to come leave the "watch-and-wait" strategy in newly diagnosed asymptomatic follicular lymphoma patients?
    Rueda A; Casanova M; Redondo M; Pérez-Ruiz E; Medina-Pérez A
    BMC Cancer; 2012 May; 12():210. PubMed ID: 22650448
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial.
    Ardeshna KM; Qian W; Smith P; Braganca N; Lowry L; Patrick P; Warden J; Stevens L; Pocock CF; Miall F; Cunningham D; Davies J; Jack A; Stephens R; Walewski J; Ferhanoglu B; Bradstock K; Linch DC
    Lancet Oncol; 2014 Apr; 15(4):424-35. PubMed ID: 24602760
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Peripheral blood lymphocyte/monocyte ratio predicts outcome in follicular lymphoma and in diffuse large B-cell lymphoma patients in the rituximab era.
    Belotti A; Doni E; Bolis S; Rossini F; Casaroli I; Pezzatti S; Pogliani EM; Pioltelli PE
    Clin Lymphoma Myeloma Leuk; 2015 Apr; 15(4):208-13. PubMed ID: 25468321
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Cost-effectiveness analysis of maintenance therapy with rituximab in patients with follicular lymphoma responding to induction therapy at the first line].
    Castro Gómez AJ; López-Guillermo A; Rueda Domínguez A; Salar A; Varela Moreno C; Rubio-Terrés C
    Rev Esp Salud Publica; 2012; 86(2):163-76. PubMed ID: 22991059
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rituximab maintenance for the treatment of patients with follicular lymphoma: an updated systematic review and meta-analysis of randomized trials.
    Vidal L; Gafter-Gvili A; Salles G; Dreyling MH; Ghielmini M; Hsu Schmitz SF; Pettengell R; Witzens-Harig M; Shpilberg O
    J Natl Cancer Inst; 2011 Dec; 103(23):1799-806. PubMed ID: 22021664
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial.
    Coiffier B; Osmanov EA; Hong X; Scheliga A; Mayer J; Offner F; Rule S; Teixeira A; Walewski J; de Vos S; Crump M; Shpilberg O; Esseltine DL; Zhu E; Enny C; Theocharous P; van de Velde H; Elsayed YA; Zinzani PL;
    Lancet Oncol; 2011 Aug; 12(8):773-84. PubMed ID: 21724462
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Follicular lymphoma: 2011 update on diagnosis and management.
    Freedman A
    Am J Hematol; 2011 Sep; 86(9):768-75. PubMed ID: 21850659
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is there a role for "watch and wait" in follicular lymphoma in the rituximab era?
    Kahl B
    Hematology Am Soc Hematol Educ Program; 2012; 2012():433-8. PubMed ID: 23233615
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Has single-agent rituximab replaced watch-and-wait for a patient with asymptomatic low-grade follicular lymphoma?
    Lowry L; Ardeshna KM
    Cancer J; 2012; 18(5):390-5. PubMed ID: 23006942
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rituximab for the treatment of follicular lymphoma.
    Cheah CY; Lingaratnam S; Seymour JF
    Future Oncol; 2013 Sep; 9(9):1283-98. PubMed ID: 23980675
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Maintenance rituximab should be considered for patients with follicular lymphoma.
    Barr PM
    Clin Adv Hematol Oncol; 2014 Aug; 12(8):541-3. PubMed ID: 25356579
    [No Abstract]   [Full Text] [Related]  

  • 13. Rituximab maintenance therapy in indolent NHL: a clinical review.
    Buske C; Hiddemann W
    Leuk Res; 2006 Mar; 30 Suppl 1():S11-5. PubMed ID: 16750673
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rituximab in indolent lymphomas.
    Sousou T; Friedberg J
    Semin Hematol; 2010 Apr; 47(2):133-42. PubMed ID: 20350660
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Frontline rituximab monotherapy induction versus a watch and wait approach for asymptomatic advanced-stage follicular lymphoma: A cost-effectiveness analysis.
    Prica A; Chan K; Cheung M
    Cancer; 2015 Aug; 121(15):2637-45. PubMed ID: 25877511
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rituximab for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkin's lymphoma.
    Boland A; Bagust A; Hockenhull J; Davis H; Chu P; Dickson R
    Health Technol Assess; 2009 Sep; 13 Suppl 2():41-8. PubMed ID: 19804688
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Follicular lymphoma: first-line treatment without chemotherapy for follicular lymphoma.
    Reagan PM; Friedberg JW
    Curr Treat Options Oncol; 2015 Jul; 16(7):32. PubMed ID: 26031546
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined lenalidomide, low-dose dexamethasone, and rituximab achieves durable responses in rituximab-resistant indolent and mantle cell lymphomas.
    Ahmadi T; Chong EA; Gordon A; Aqui NA; Nasta SD; Svoboda J; Mato AR; Schuster SJ
    Cancer; 2014 Jan; 120(2):222-8. PubMed ID: 24122387
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of the introduction of rituximab in first-line follicular lymphoma: a retrospective study of 247 unselected patients referred to a single institution with a long-term follow-up.
    Nicolas-Virelizier E; Ségura-Ferlay C; Ghesquières H; Chassagne-Clément C; Gargi T; Biron P; Belhabri A; Rey P; Faurie P; Chabaud S; Sebban C
    Hematol Oncol; 2015 Mar; 33(1):1-8. PubMed ID: 24496668
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rituximab with or without bevacizumab for the treatment of patients with relapsed follicular lymphoma.
    Hainsworth JD; Greco FA; Raefsky EL; Thompson DS; Lunin S; Reeves J; White L; Quinn R; DeBusk LM; Flinn IW
    Clin Lymphoma Myeloma Leuk; 2014 Aug; 14(4):277-83. PubMed ID: 24679633
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.